Some of the most surprising data presented at the GI Symposium in January 2011 in San Francisco was the negative result of the European trial called AVANT.

Dr. HJ Lenz

In that clinical trial patients who underwent a curative resection for colon cancer received either FOLFOX or FOLFOX with Avastin® (bevacizumab) treatment after their surgery. Chemotherapy was given over 6 months, but patients who were randomly selected for Avastin received 6 months with chemotherapy and additional  6 months alone after chemotherapy ended for a total of 12 months of Avastin. Read the rest of this entry »

Dr. Lenz

We are making significant progress in understanding what genetic alterations in tumors really mean.

Over the last two years, we have learned or the first time that there is an alteration in a gene called KRAS in colon cancer, and tumors which have this mutation do not respond to treatment with Erbitux® (cetuximab) or Vectibix® (panitumumab).

This is the first time we have a marker to test for sensitivity of an antibody we have to treat colon cancer.

It is very important to know that patients with tumors who carry a KRAS mutation (alteration) are not doing worse overall. They just don’t have any benefit from an antibody which targets the Epithelial Growth Factor Receptor (EGFR). Read the rest of this entry »

We are getting more sophisticated in evaluating biomarkers. It is a serious challenge to develop a biomarker which is validated and can be used with confidence in the clinic. We have only ONE biomarker which is kras mutation a marker to predict resistance to EGFR inhibitors

I just reported in my previous blog that not all of the mutations are equal.  Some of them act like wild- type (normal), and patients with these mutations should be considered for Erbitux therapy. Patients with wild-type KRAS  have a higher chance of response from Erbitux, but that does not predict response.

There have been a lot of efforts to increase the predictive value of wild-type KRAS for response. Many potential candidates have been studied. These include PTEN, EGFR ligands, BRAF and PI3K mutations. Most of the studies revealed controversial findings. Some found an associations and other did not.

Why is that? Read the rest of this entry »

Dr. Lenz

Recent data suggest that some KRAS mutations act like normal or wild-type KRAS. Maybe for those mutations, Erbitux could be used for treatment.

A recent publication in the Journal of the American Medical Association by Dr. Sabine Tejpar using an international collaboration showed that some mutations act like wild-type KRAS and that these patients actually may benefit from Erbitux therapy.

Maybe we were wrong thinking that all KRAS mutations are the same. Haven’t we learned from our mistakes before? Read the rest of this entry »

Dr. Lenz

The short answer is YES, but obviously this depends on many factors. We usually recommend that patients complete one or two cycles of chemotherapy to see if there are many side effects or not. If patients tolerate the first two cycles well, usually there is no accumulating side effect expected except for neurotoxicity with oxaliplatin down the road.

Personally I think going back to work is important, because it gives the patient some normality and forces him or her to think about something else than the cancer. However this may not apply for everyone, so discussions with your doctor and family are critical. It is important to plan how you will continue to work while you get cancer treatment. I see patients on Mondays and Thursdays, so patients who want to continue to work or may have to continue to work to keep their insurance, usually get treatments on Thursdays, giving them the weekend to recover. Patients who want to spend the weekend with the family choose Monday treatments, giving them time to recover for the weekend. Here are some tips which might help you to better manage your time and work: Read the rest of this entry »